Is RPRX or RXRX more undervalued in 2026?

CirclFi compares Royalty Pharma plc (RPRX) and Recursion Pharmaceuticals, Inc. (RXRX) using 13 institutional-grade valuation models. RPRX has a Quality of Company score of 8.4/10 while RXRX scores 6.5/10.

Which is a better buy — RPRX or RXRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do RPRX and RXRX valuations compare?

RPRX at $54.48 and RXRX at $3.44 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

RPRX vs RXRX Valuation Comparison 2026 — Intrinsic Value Analysis

RPRX

Biotechnology

Royalty Pharma plc

Quality

8.4

out of 10

Value Trap

SAFE

Price

$54.48

Last close

Models

12/13

Active

RXRX

Biotechnology

Recursion Pharmaceuticals, Inc.

Quality

6.5

out of 10

Value Trap

LOW

Price

$3.44

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	RPRX Fair Value	RPRX Upside	RXRX Fair Value	RXRX Upside
Bayesian DCF	Intrinsic	$57.58	+5.7%	$1.52	-55.8%
Earnings Power Value	Intrinsic	$1.77	-96.8%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	—	—	$1.99	-42.2%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for RPRX vs RXRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RPRX vs RXRX — Which Stock Is More Undervalued?

RPRX scores higher with a 8.4/10 quality rating vs RXRX's 6.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Royalty Pharma plc (RPRX) and Recursion Pharmaceuticals, Inc. (RXRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RPRX currently trades at $54.48 with a QOC of 8.4/10, while RXRX trades at $3.44 with a QOC of 6.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).